A Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

132.790

Open

131.820

VWAP

131.31

Vol

2.46M

Mkt Cap

37.04B

Low

129.990

Amount

322.54M

EV/EBITDA(TTM)

20.39

Total Shares

282.43M

38.43B

EV/OCF(TTM)

26.47

P/S(TTM)

5.13

Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.

Events Timeline

(ET)

2026-07-01

08:30:00

Agilent Launches AI-Powered xCELLigence RTCA eSight Software

2026-06-25 (ET)

2026-06-25

08:30:00

Agilent Completes Acquisition of Biocare Medical

2026-06-03 (ET)

2026-06-03

07:10:00

Agilent Technologies Partners with OpenAI and BCG to Accelerate AI Deployment

2026-06-02 (ET)

2026-06-02

16:30:00

Agilent Technologies Receives FDA Approval for Expanded PD-L1 Testing Indications

News

2.0

06-15PRnewswire

Honeywell Board Approves Aerospace Spin-Off

8.5

06-05PRnewswire

Honeywell Announces Aerospace Spin-Off Plan

9.0

06-03seekingalpha

FDA Expands Agilent's PD-L1 Test Indication for Keytruda Use

7.5

06-03Newsfilter

Agilent Partners with OpenAI and BCG to Accelerate AI Deployment

8.5

06-02Newsfilter

Agilent Receives FDA Approval for Expanded PD-L1 Testing

6.5

06-02seekingalpha

Valuation Analysis of U.S. Healthcare Stocks

13 Analyst Rating

Wall Street analysts forecast A stock price to rise

12 Buy

1 Hold

0 Sell

Strong Buy

Current: 0.000

Low

160.00

Averages

171.67

High

180.00

Current: 0.000

Low

160.00

Averages

171.67

High

180.00

Evercore ISI

Vijay Kumar

NULL

Outperform

maintain

$144 -> $148

AI Analysis

2026-07-06

New

Reason

Evercore ISI

Vijay Kumar

Price Target

$144 -> $148

AI Analysis

2026-07-06

New

maintain

NULL

Outperform

Reason

Evercore ISI analyst Vijay Kumar raised the firm's price target on Agilent to $148 from $144 and keeps an Outperform rating on the shares. The firm's Q2 preview for MedTech, Life Sciences Tools, and Diagnostics highlights generally healthy procedure volumes and capital expenditure trends across the sector, the analyst tells investors in a research note.

Bernstein

Eve Burstein

initiated

$155

2026-06-26

Reason

Bernstein

Eve Burstein

Price Target

$155

2026-06-26

initiated

Reason

Bernstein analyst Eve Burstein resumed coverage of Agilent with an Outperform rating and $155 price target following a return from maternity leave. \"Many things\" are going right for the life science tools and diagnostics sector, the analyst tells investors in a research note. The firm says new drug approvals, trial starts, and funding are all better in the last 12 months versus the 12 months prior. Bernstein believes funding will start translating into customer spend while re-shoring will drive incremental investment at a time when AI-driven demand for semiconductor-related tools will continue to grow.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for A

Unlock Now

Valuation Metrics

The current forward P/E ratio for Agilent Technologies Inc (A.N) is 19.46, compared to its 5-year average forward P/E of 24.74. For a more detailed relative valuation and DCF analysis to assess Agilent Technologies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

24.74

Current PE

19.46

Overvalued PE

28.70

Undervalued PE

20.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

20.14

Current EV/EBITDA

17.88

Overvalued EV/EBITDA

23.12

Undervalued EV/EBITDA

17.15

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

5.63

Current PS

4.67

Overvalued PS

6.47

Undervalued PS

4.80

Financials

AI Analysis

Annual

Quarterly

Whales Holding A

Candriam, Société En Commandite Par Actions

Holding

+12.68%

3M Return

Pictet Asset Management Limited

Holding

+12.63%

3M Return

Aquatic Capital Management LLC

Holding

+10.89%

3M Return

Champlain Investment Partners, LLC

Holding

+10.69%

3M Return

Cantillon Capital Management LLC

Holding

+9.44%

3M Return

Trading Trends

People Also Watch

Frequently Asked Questions

What is Agilent Technologies Inc (A) stock price today?

The current price of A is 131.14 USD — it has increased 0.41

What is Agilent Technologies Inc (A)'s business?

What is the price predicton of A Stock?

Wall Street analysts forecast A stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for A is171.67 USD with a low forecast of 160.00 USD and a high forecast of 180.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.